论文部分内容阅读
目的探讨口服孟鲁司特钠辅助治疗支气管哮喘的临床效果。方法选取2013年1月—2016年1月重庆市荣昌区人民医院收治的100例支气管哮喘患者。按入院先后顺序分为观察组与对照组,各50例。两组患者均吸入布地奈德和沙美特罗替卡松粉,观察组患者在此基础上加用孟鲁斯特纳治疗,比较两组患者治疗前后肺功能[用力肺活量(FVC)、第1秒用力呼气末容积(FEV1)、呼气峰值流速(PEF)]、临床疗效及不良反应发生情况。结果治疗前两组患者FVC、PEF、PEV_1比较,差异无统计学意义(P>0.05);治疗后观察组患者FVC、PEF、PEV_1高于对照组,差异有统计学意义(P<0.05);治疗后两组患者FVC、PEF、PEV_1高于治疗前,差异有统计学意义(P<0.05)。观察组患者治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗过程中两组患者均未出现严重、影响治疗和研究的不良反应。结论口服孟鲁司特钠辅助治疗支气管哮喘的临床效果确切,可有效改善患者肺功能,且不良反应少。
Objective To investigate the clinical effect of oral montelukast sodium adjuvant treatment of bronchial asthma. Methods From January 2013 to January 2016, 100 patients with bronchial asthma admitted to Rongchang District People’s Hospital of Chongqing were enrolled. According to the sequence of hospital admission was divided into observation group and control group, 50 cases each. Both groups inhaled budesonide and salmeterol trussose powder, the observation group patients were treated with montelukastone on the basis of this study. Before and after treatment, lung function [forced vital capacity (FVC), group 1 Second forced end-expiratory volume (FEV1), peak expiratory flow rate (PEF)], clinical efficacy and adverse reactions. Results There was no significant difference in FVC, PEF and PEV_1 between the two groups before treatment (P> 0.05). After treatment, FVC, PEF and PEV_1 in the observation group were higher than those in the control group (P <0.05). After treatment, the FVC, PEF and PEV_1 in two groups were higher than those before treatment, the difference was statistically significant (P <0.05). The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). During the course of treatment, no serious adverse reactions were found in both groups, which affected the treatment and study. Conclusion Oral Montelukast adjuvant treatment of bronchial asthma clinical effect is exact, can effectively improve lung function in patients with less adverse reactions.